Excellent quality and fast dispatch
Products arrived well-packaged with COA documentation included. Really appreciate the clear research-only labelling — exactly what I needed for my lab work.
James R.
Sydney, AU
Amylin + GLP-1 Dual-Pathway Blend
Cagrisema Australia
Everything researchers need to know about Cagrisema — mechanism, published dosing protocols, side effect profiles, reconstitution, and how to source third-party tested Cagrisema in Australia.
Quick facts
- Also known as: Cagrilintide + Semaglutide Blend
- Form: Lyophilised powder (>99% purity)
- Variants: 5 mg
- 🇦🇺 3–5 business days
March 2025
Best local supplier I've found
Ordered three times now. HPLC verification results have been consistent each time. The pathway browsing structure makes it much easier to compare compounds.
Sarah K.
Melbourne, AU
Fast shipping, great documentation
Same-day dispatch on my last two orders. The batch COA was easy to locate and the product information pages are genuinely useful for research planning.
Michael T.
Brisbane, AU
Representative of verified researcher feedback.
Overview
What Is Cagrisema?
Cagrisema is a combination research peptide containing Cagrilintide (an amylin analogue) and Semaglutide (a GLP-1 agonist). This blend targets two distinct satiety pathways — amylin-mediated hindbrain signaling and GLP-1-mediated hypothalamic pathways — offering researchers a tool to study synergistic metabolic effects.
Also known as Cagrilintide + Semaglutide Blend, Cagrisema is supplied as a lyophilised research peptide for laboratory use only. Published data indicates the combination of amylin and GLP-1 pathway activation produces greater reductions in food intake than either agent alone in preclinical models. The amylin component adds a complementary mechanism via area postrema activation.
Mechanism
How Cagrisema Works — Research Mechanism
Published data indicates the combination of amylin and GLP-1 pathway activation produces greater reductions in food intake than either agent alone in preclinical models. The amylin component adds a complementary mechanism via area postrema activation.
- Cagrilintide: long-acting amylin receptor agonist via area postrema
- Semaglutide: GLP-1 receptor agonist via hypothalamic pathways
- Dual satiety pathway activation — complementary mechanisms
- Greater food intake reduction than either agent alone in preclinical models
- Co-formulated blend for dual-pathway metabolic research
Research reference
Cagrisema Dosage — Published Research Protocols
The following reference points are drawn from published research literature. These figures are provided for research reference only and do not constitute dosing recommendations. Cagrisema is sold strictly for laboratory research use.
| Protocol tier | Published research detail |
|---|---|
| Research reference | Published literature varies by model and endpoint — consult primary sources for protocol-specific dosing in laboratory settings |
| Administration route | Subcutaneous injection is most common in published peptide research protocols |
| Frequency | Dosing frequency depends on compound half-life and research design — daily to weekly intervals reported in literature |
| Available vial sizes | 5 mg — select based on your laboratory protocol requirements |
| Titration | Many research protocols start at lower doses and escalate to assess receptor response and tolerability in models |
Research use only: FOR LABORATORY RESEARCH USE ONLY. Not for human consumption, injection, or therapeutic use. All products are sold strictly as research chemicals. By purchasing, you confirm you are 18+ and agree to use products solely for legitimate research purposes.
Safety research
Cagrisema Side Effects — Research Findings
Side effect profiles documented in published Cagrisema research depend on dose, route of administration, and model system. The following are commonly reported findings from research literature — not from personal use contexts.
- Gastrointestinal effects (nausea, vomiting, diarrhoea) commonly reported in incretin-class research
- Injection site reactions at subcutaneous administration sites
- Appetite suppression observed dose-dependently in metabolic research models
- Most events in published trials reported as mild to moderate and dose-dependent
Handling
Reconstituting Cagrisema
Cagrisema is supplied as a lyophilised powder and must be reconstituted before use in laboratory protocols. Use bacteriostatic water (0.9% benzyl alcohol) for multi-dose vials. Inject diluent slowly down the inside wall of the vial — do not shake vigorously.
Bacteriostatic water is available from EvoPeak. Store reconstituted peptide at 2–8°C and lyophilised powder at −20°C.
Shop bacteriostatic waterAustralia
How to Get Cagrisema in Australia
Researchers in Australia can source Cagrisema through EvoPeak — a local supplier offering third-party tested research compounds with batch-specific COA documentation and domestic shipping.
- 1
Browse Cagrisema variants (5 mg) on the EvoPeak product page
- 2
Review the certificate of analysis (COA) for HPLC purity and mass spectrometry identity verification
- 3
Select your vial size and add to cart — prices include GST with same-day Australian dispatch
- 4
Receive your order with batch-specific quality documentation for laboratory traceability
Quality Standard
Research compounds need evidence, not guesswork.
Every shopping path leads back to the same core standard: research-use positioning, third-party quality signals, transparent documentation, and careful handling guidance.
HPLC/MS verified
Purity and identity checks support confident compound selection for controlled research.
Endotoxin screened
Quality review extends beyond purity so researchers can evaluate handling risk.
Batch documentation
COA-first product pages keep quality signals close to every purchase decision.
Australia shipped
Local fulfilment keeps delivery predictable for Australian research customers.
FAQ
Cagrisema — Common Questions
What is Cagrisema?
Amylin analogue + GLP-1 agonist blend for dual-pathway metabolic research. Cagrisema is a combination research peptide containing Cagrilintide (an amylin analogue) and Semaglutide (a GLP-1 agonist). This blend targets two distinct satiety pathways — amylin-mediated hindbrain… It is supplied for laboratory research use only.
What is the Cagrisema dosage used in research?
Published research uses varying doses depending on the model and endpoint. EvoPeak supplies 5 mg vials. All dosage information is for research reference only and does not constitute recommendations.
What are the side effects of Cagrisema?
Side effect profiles in published research depend on dose, route, and model system. Consult primary literature for compound-specific findings. All information is drawn from research contexts, not personal use.
Can I buy Cagrisema in Australia?
Yes. EvoPeak supplies research-grade Cagrisema to Australian researchers with HPLC/MS verification, batch-specific COA documentation, and domestic shipping. Products are for laboratory research use only.
How do I get Cagrisema in Australia?
Order from the EvoPeak shop page, select your vial size, review the COA, and checkout with local Australian fulfilment.
How do I reconstitute Cagrisema?
Cagrisema is supplied as lyophilised powder. Reconstitute with bacteriostatic water, inject diluent slowly down the vial wall without shaking, and store at 2–8°C once reconstituted. Bacteriostatic water is available from EvoPeak.
What purity standard does EvoPeak Cagrisema meet?
Every batch undergoes HPLC purity analysis (targeting >99%), mass spectrometry identity verification, and endotoxin screening. Batch-specific COAs are available on the product page.
Is cagrisema peptide the same as Cagrilintide + Semaglutide Blend?
Cagrisema is also known as Cagrilintide + Semaglutide Blend. Both refer to the same research compound supplied by EvoPeak.
Related compounds
Explore related research peptides
Ready to order Cagrisema?
Third-party HPLC/MS tested with batch-specific COA documentation. Shipped from Australia for laboratory research use only.